Matches in SemOpenAlex for { <https://semopenalex.org/work/W4200326987> ?p ?o ?g. }
- W4200326987 endingPage "100356" @default.
- W4200326987 startingPage "100356" @default.
- W4200326987 abstract "•PanCO is the first prospective study of intratumoural 32P microparticles for locally advanced pancreatic cancer (LAPC).•This single-arm study assessed a novel brachytherapy (32P microparticles) combined with standard-of-care chemotherapy.•Treatment-emergent adverse events attributable to 32P microparticle implantation were relatively infrequent.•Local disease control rate at 16 weeks (82%) and resection rate (20%) suggest a clinical benefit of 32P microparticles.•The results suggest that 32P microparticles may address a significant unmet need in patients with unresectable LAPC. BackgroundUnresectable locally advanced pancreatic cancer (LAPC) is generally managed with chemotherapy or chemoradiotherapy, but prognosis is poor with a median survival of ∼13 months (or up to 19 months in some studies). We assessed a novel brachytherapy device, using phosphorous-32 (32P) microparticles, combined with standard-of-care chemotherapy.Patients and methodsIn this international, multicentre, single-arm, open-label pilot study, adult patients with histologically or cytologically proven unresectable LAPC received 32P microparticles, via endoscopic ultrasound-guided fine-needle implantation, planned for week 4 of 5-fluorouracil, leucovorin, irinotecan and oxaliplatin (FOLFIRINOX) or gemcitabine/nab-paclitaxel chemotherapy, per investigator’s choice. The primary endpoint was safety and tolerability measured using Common Terminology Criteria for Adverse Events version 4.0. The lead efficacy endpoint was local disease control rate at 16 weeks.ResultsFifty patients were enrolled and received chemotherapy [intention-to-treat (ITT) population]. Forty-two patients received 32P microparticle implantation [per protocol (PP) population]. A total of 1102 treatment-emergent adverse events (TEAEs) were reported in the ITT/safety population (956 PP), of which 167 (139 PP) were grade ≥3. In the PP population, 41 TEAEs in 16 (38.1%) patients were possibly or probably related to 32P microparticles or implantation procedure, including 8 grade ≥3 in 3 (7.1%) patients, compared with 609 TEAEs in 42 (100%) patients attributed to chemotherapy, including 67 grade ≥3 in 28 patients (66.7%). The local disease control rate at 16 weeks was 82.0% (95% confidence interval: 68.6% to 90.9%) (ITT) and 90.5% (95% confidence interval: 77.4% to 97.3%) (PP). Tumour volume, carbohydrate antigen 19-9 levels, and metabolic tumour response at week 12 improved significantly. Ten patients (20.0% ITT; 23.8% PP) had surgical resection and median overall survival was 15.2 and 15.5 months for ITT and PP populations, respectively.ConclusionsEndoscopic ultrasound-guided 32P microparticle implantation has an acceptable safety profile. This study also suggests clinically relevant benefits of combining 32P microparticles with standard-of-care systemic chemotherapy for patients with unresectable LAPC. Unresectable locally advanced pancreatic cancer (LAPC) is generally managed with chemotherapy or chemoradiotherapy, but prognosis is poor with a median survival of ∼13 months (or up to 19 months in some studies). We assessed a novel brachytherapy device, using phosphorous-32 (32P) microparticles, combined with standard-of-care chemotherapy. In this international, multicentre, single-arm, open-label pilot study, adult patients with histologically or cytologically proven unresectable LAPC received 32P microparticles, via endoscopic ultrasound-guided fine-needle implantation, planned for week 4 of 5-fluorouracil, leucovorin, irinotecan and oxaliplatin (FOLFIRINOX) or gemcitabine/nab-paclitaxel chemotherapy, per investigator’s choice. The primary endpoint was safety and tolerability measured using Common Terminology Criteria for Adverse Events version 4.0. The lead efficacy endpoint was local disease control rate at 16 weeks. Fifty patients were enrolled and received chemotherapy [intention-to-treat (ITT) population]. Forty-two patients received 32P microparticle implantation [per protocol (PP) population]. A total of 1102 treatment-emergent adverse events (TEAEs) were reported in the ITT/safety population (956 PP), of which 167 (139 PP) were grade ≥3. In the PP population, 41 TEAEs in 16 (38.1%) patients were possibly or probably related to 32P microparticles or implantation procedure, including 8 grade ≥3 in 3 (7.1%) patients, compared with 609 TEAEs in 42 (100%) patients attributed to chemotherapy, including 67 grade ≥3 in 28 patients (66.7%). The local disease control rate at 16 weeks was 82.0% (95% confidence interval: 68.6% to 90.9%) (ITT) and 90.5% (95% confidence interval: 77.4% to 97.3%) (PP). Tumour volume, carbohydrate antigen 19-9 levels, and metabolic tumour response at week 12 improved significantly. Ten patients (20.0% ITT; 23.8% PP) had surgical resection and median overall survival was 15.2 and 15.5 months for ITT and PP populations, respectively. Endoscopic ultrasound-guided 32P microparticle implantation has an acceptable safety profile. This study also suggests clinically relevant benefits of combining 32P microparticles with standard-of-care systemic chemotherapy for patients with unresectable LAPC." @default.
- W4200326987 created "2021-12-31" @default.
- W4200326987 creator A5005457126 @default.
- W4200326987 creator A5028869763 @default.
- W4200326987 creator A5029339790 @default.
- W4200326987 creator A5030187765 @default.
- W4200326987 creator A5034486818 @default.
- W4200326987 creator A5035249153 @default.
- W4200326987 creator A5037991283 @default.
- W4200326987 creator A5042102836 @default.
- W4200326987 creator A5045290531 @default.
- W4200326987 creator A5060058983 @default.
- W4200326987 creator A5063738443 @default.
- W4200326987 creator A5070415176 @default.
- W4200326987 creator A5078792014 @default.
- W4200326987 creator A5084034524 @default.
- W4200326987 creator A5084486649 @default.
- W4200326987 creator A5086605611 @default.
- W4200326987 date "2022-02-01" @default.
- W4200326987 modified "2023-10-11" @default.
- W4200326987 title "Results of a single-arm pilot study of 32P microparticles in unresectable locally advanced pancreatic adenocarcinoma with gemcitabine/nab-paclitaxel or FOLFIRINOX chemotherapy" @default.
- W4200326987 cites W1592992548 @default.
- W4200326987 cites W1964575456 @default.
- W4200326987 cites W2031664566 @default.
- W4200326987 cites W2066681450 @default.
- W4200326987 cites W2103711657 @default.
- W4200326987 cites W2107780185 @default.
- W4200326987 cites W2111085711 @default.
- W4200326987 cites W2153716722 @default.
- W4200326987 cites W2155263737 @default.
- W4200326987 cites W2156302506 @default.
- W4200326987 cites W2168645047 @default.
- W4200326987 cites W2346921980 @default.
- W4200326987 cites W2413386818 @default.
- W4200326987 cites W2415000849 @default.
- W4200326987 cites W2589807181 @default.
- W4200326987 cites W2624653214 @default.
- W4200326987 cites W2724129713 @default.
- W4200326987 cites W2739482112 @default.
- W4200326987 cites W2773815625 @default.
- W4200326987 cites W2782917551 @default.
- W4200326987 cites W2801301689 @default.
- W4200326987 cites W2901299122 @default.
- W4200326987 cites W2943065688 @default.
- W4200326987 cites W2946159987 @default.
- W4200326987 cites W2958644749 @default.
- W4200326987 cites W2982312829 @default.
- W4200326987 cites W3000487074 @default.
- W4200326987 cites W3022250631 @default.
- W4200326987 cites W3023465048 @default.
- W4200326987 cites W3041898385 @default.
- W4200326987 cites W3050061013 @default.
- W4200326987 cites W3092291343 @default.
- W4200326987 cites W4211208840 @default.
- W4200326987 cites W4251725022 @default.
- W4200326987 doi "https://doi.org/10.1016/j.esmoop.2021.100356" @default.
- W4200326987 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34953400" @default.
- W4200326987 hasPublicationYear "2022" @default.
- W4200326987 type Work @default.
- W4200326987 citedByCount "6" @default.
- W4200326987 countsByYear W42003269872022 @default.
- W4200326987 countsByYear W42003269872023 @default.
- W4200326987 crossrefType "journal-article" @default.
- W4200326987 hasAuthorship W4200326987A5005457126 @default.
- W4200326987 hasAuthorship W4200326987A5028869763 @default.
- W4200326987 hasAuthorship W4200326987A5029339790 @default.
- W4200326987 hasAuthorship W4200326987A5030187765 @default.
- W4200326987 hasAuthorship W4200326987A5034486818 @default.
- W4200326987 hasAuthorship W4200326987A5035249153 @default.
- W4200326987 hasAuthorship W4200326987A5037991283 @default.
- W4200326987 hasAuthorship W4200326987A5042102836 @default.
- W4200326987 hasAuthorship W4200326987A5045290531 @default.
- W4200326987 hasAuthorship W4200326987A5060058983 @default.
- W4200326987 hasAuthorship W4200326987A5063738443 @default.
- W4200326987 hasAuthorship W4200326987A5070415176 @default.
- W4200326987 hasAuthorship W4200326987A5078792014 @default.
- W4200326987 hasAuthorship W4200326987A5084034524 @default.
- W4200326987 hasAuthorship W4200326987A5084486649 @default.
- W4200326987 hasAuthorship W4200326987A5086605611 @default.
- W4200326987 hasBestOaLocation W42003269871 @default.
- W4200326987 hasConcept C121608353 @default.
- W4200326987 hasConcept C126322002 @default.
- W4200326987 hasConcept C141071460 @default.
- W4200326987 hasConcept C143998085 @default.
- W4200326987 hasConcept C168563851 @default.
- W4200326987 hasConcept C197934379 @default.
- W4200326987 hasConcept C203092338 @default.
- W4200326987 hasConcept C2776694085 @default.
- W4200326987 hasConcept C2777148230 @default.
- W4200326987 hasConcept C2777416452 @default.
- W4200326987 hasConcept C2777793932 @default.
- W4200326987 hasConcept C2778375690 @default.
- W4200326987 hasConcept C2778424827 @default.
- W4200326987 hasConcept C2780210213 @default.
- W4200326987 hasConcept C2780258809 @default.
- W4200326987 hasConcept C2780259306 @default.
- W4200326987 hasConcept C2780962732 @default.
- W4200326987 hasConcept C2908647359 @default.